By Jack Zheng, MS Pharmacy — Founder of MIHIYO Labs
Summary
An oral dissolving strip is usually the cleaner format when the goal is a repeatable low-dose supplement that also has to travel well. A liquid syrup asks the user to measure every dose, and measurement error is not small: in one clinical study, droppers showed a mean 33 percent error, versus 2 percent for oral syringes. Syrups also carry the stability burdens of water, including preservative and microbiological constraints. An oral dissolving strip (ODS) fixes the dose in a dry unit and can hold mucosal contact before swallowing. For MIHIYO Labs Sleep-Support, that repeatability is the formulation reason to prefer film over syrup.
Oral dissolving strip vs liquid syrup: which format is more defensible for daily use?
For a fixed low-dose supplement, an oral dissolving strip is usually the more defensible format. A liquid syrup can work, but it asks the user to measure the dose correctly, swallow or hold it correctly, store a water-based product correctly, and carry a bottle that is bulkier and easier to spill than a sealed film pouch. A strip does more of that work upstream.
That is the formulation lens I use. I am not asking which format sounds more natural. I am asking which format gives the same labeled dose, in the same physical condition, with the least room for everyday user error. For a low-dose sleep product, that answer is usually film.
Why does a liquid syrup create variability before absorption even starts?
A syrup is already dissolved, which sounds simple until you look at the point of use. The user still has to measure the volume. That means the final dose depends on the tool, the liquid viscosity, the fill line, the viewing angle, and the user's hand.12 The active may be formulated correctly in the bottle, but the delivered dose is still reconstructed every time the cap comes off.
The error size is not trivial. In a clinical-setting study of adults using common oral-liquid devices, Elliott and colleagues found mean error of 2 percent for oral syringes, 14 percent for cups, and 33 percent for droppers.2 The dropper tended to underdose, while cups drifted in the other direction. That is exactly the kind of avoidable noise I try to remove in supplement design.
The same pattern appears in home use. Bayraktar Balikci and colleagues observed caregivers measuring a 2.5 mL target dose and found that cups accounted for 55 percent of errors, droppers for 22 percent, spoons for 17 percent, and oral syringes for only 4 percent.3 The study was run on medicines, not supplements, but the dosing physics are the same. Measuring small liquid volumes is a user-performance problem, not just a labeling problem.
The FDA's 2011 guidance on oral liquid dosage devices exists because these errors are common enough to justify formal matching of device markings and labeled directions.1 That is a useful reality check. A unit-dose strip does not carry that measuring-device complexity.
An oral dissolving strip changes the sequence. The active is cast into a defined film area, sealed as a single unit, and placed directly in the mouth without any meniscus reading, drop counting, or tool selection. The question becomes placement, not measurement. That is a simpler system, and simpler systems usually fail less often.
What changes once the dose reaches the mouth?
Most syrups are designed to be measured and swallowed, not to remain at one oral site. Even if a user briefly holds a syrup in the mouth, the liquid spreads, dilutes in saliva, and is easy to swallow early. The oral mucosa is the vascular lining of the cheek, lip, and tongue underside. It can absorb some compounds, but only while the dose stays in effective contact with it.45
Bartlett and van der Voort Maarschalk make this point clearly in their review of asenapine pharmacokinetics. The oral cavity can support transmucosal absorption, but liquid residence is short and whatever does not partition into tissue soon enough is swallowed.5 Once swallowed, the dose becomes gastrointestinal exposure and again faces first-pass metabolism, which is the loss that occurs through the gut wall and liver before the compound reaches general circulation.
Films were built to manage that exact problem. Jacob and colleagues describe buccal films as systems designed to maintain intimate association with the mucosa and prolong residence at the absorption site.4 The film is not just a convenient wrapper around an ingredient. It is a mechanical answer to washout.
The contact-time evidence is why I take the geometry seriously. In the microdosed midazolam study by Grass and colleagues, absolute bioavailability was 27.8 percent when the dose was swallowed as a solution and 66.1 percent after 100 seconds of buccal contact.6 Same molecule, different contact window. A syrup is not engineered to hold that window. A film is. The molecule still matters, but the design potential is different from the start.
How do liquid syrups and ODS compare on the dimensions that matter?
| Dimension | Liquid syrup | Oral dissolving strip (ODS) | Source |
|---|---|---|---|
| At-use dose accuracy | User-measured; mean error 33% with droppers, 14% with cups, 2% with syringes in one study | Unit-dose film removes the measuring step entirely | FDA, 2011; Elliott et al., 2014 |
| Home-use consistency | Caregiver dosing errors clustered around cups and droppers for a 2.5 mL target | Single-dose pouch avoids tool choice and line reading | Bayraktar Balikci et al., 2024 |
| Route after administration | Usually swallowed liquid; brief oral contact is hard to standardize | Thin film can hold directed mucosal contact before the remainder is swallowed | Jacob et al., 2021; Bartlett et al., 2012; Grass et al., 2021 |
| Stability burden | Water-based system faces preservative, pH, microbial, and sensory drift issues over time | Dry film is generally easier to stabilize and transport | Jitca et al., 2023; Ozakar and Ozakar, 2021 |
| Travel and handling | Multi-dose bottle plus cap and measuring device; bulkier and easier to leak in a bag | Flat, sealed, single unit; easier to carry without spill risk | Ozakar and Ozakar, 2021 |
| Best use case | Flexible titration or users who specifically need a liquid swallowable dose | Fixed, low-to-moderate dose where repeatability and portability matter | Ozakar and Ozakar, 2021 |
Dose accuracy. This is the strongest point in the whole comparison. Elliott's device study found a 33 percent mean error with droppers and only 2 percent with syringes.2 If a syrup is packaged with a dropper, the tool itself becomes part of the formulation outcome. A strip avoids the problem because the dose is already portioned.
Route control. A syrup can only behave like a transmucosal product if the liquid stays where it should long enough to partition into tissue. That is hard to standardize. The mouth is not a beaker. Saliva, tongue movement, and swallow reflex all work against a pooled liquid.45 A film is thin, local, and purpose-built for residence. The midazolam contact-time study is useful because it isolates the one variable that changes the result: how long the dose stays against the mucosa.6
Stability and preservative burden. Water solves one manufacturing problem and creates several others. Jitca and colleagues, reviewing oral liquid dosage forms, describe the recurring constraints clearly: pH drift, preservative selection, microbiological risk, and organoleptic change over time.7 A dry film is not exempt from stability work, but it starts without a bulk water phase, which is a major simplification.
Travel and handling. This is less glamorous than pharmacokinetics, but it matters in real consumer use. Ozakar and Ozakar note that oral thin films offer accurate dosing, portability, and better physical stability than oral liquids.8 A flat sealed pouch is easier to carry discreetly than a bottle that can leak, break, or need an extra tool in the same bag.
Flexibility. The syrup does keep one honest advantage. If the product genuinely needs open-ended titration, volume gives the user a softer adjustment dial than a fixed strip. I would rather admit that clearly than pretend film is universally superior. The real question is whether the product should be flexible or repeatable. Those are not the same design goal.
What does this mean for MIHIYO Sleep-Support?
For Sleep-Support ODS, I care more about repeatable low-dose delivery than about open-ended volume adjustment. That product is built around the idea that small, well-defined melatonin exposures make more formulation sense than the oversized, vague-dose style that dominates the category. A strip supports that logic better than a syrup.
There is also a practical design reason. I would rather hand someone one sealed dose than ask them to measure a sweet liquid in low light. The strip creates a visible dosing boundary: one strip is one dose.
The comparison also fits the rest of the sleep-support evidence base. Our earlier article on melatonin strip dosage explains why I stay interested in lower, more controlled melatonin doses. The related piece on oral dissolving strip vs tincture covers the broader measurement problem from the liquid-drop side.
I want to be explicit about the evidence boundary. None of the studies cited here were run on MIHIYO products. The dosing-device papers were run on oral liquid devices, and the mucosal-contact papers were run on model pharmaceutical systems.236 I am applying dosage-form science and product-design logic, not claiming a head-to-head human trial on our own strip versus a syrup.
Where is a liquid syrup still the right choice?
A syrup still makes sense when the user truly needs a swallowable liquid, when titration by volume is the central feature, or when the payload is too high or too unpleasant for a thin film. Some actives simply fit better into liquid systems than film systems.
There are also limits on the strip side. Not every molecule permeates the oral mucosa well, and some doses make the strip too thick, too slow, or too large to be elegant. In those cases a syrup, capsule, or tablet may be the more honest format.
So the fair conclusion is not that syrup is outdated. It is that syrup prioritizes volume flexibility, while a film prioritizes fixed-dose repeatability and dry portability.
The bottom line
In an oral dissolving strip vs liquid syrup comparison, the strip usually wins when the job is a repeatable, low-dose supplement that should be stable, portable, and hard to mismeasure. Syrups can be useful, especially when titration matters, but they hand too much of the final dose to the user's measuring technique and too much of the storage problem to a water-based bottle. For MIHIYO Labs Sleep-Support, the film is not a branding preference. It is the cleaner engineering choice.
References
- U.S. Food and Drug Administration. Guidance for Industry: Dosage Delivery Devices for Orally Ingested OTC Liquid Drug Products. 2011. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/dosage-delivery-devices-orally-ingested-otc-liquid-drug-products>
- Elliott JP, McConaha J, Cornish N, Bunk E, Hilton L, Modany A, Bucker I. Influence of Viscosity and Consumer Use on Accuracy of Oral Medication Dosing Devices. Journal of Pharmacy Technology. 2014;30(4):111-117. DOI: 10.1177/8755122514533780. <https://pmc.ncbi.nlm.nih.gov/articles/PMC5990148/>
- Bayraktar Balikci B, Yilmaz G, Yildizdas D, et al. Accuracy of liquid drug dose measurements using different tools by caregivers: a prospective observational study. European Journal of Pediatrics. 2024. PMID: 37875630. DOI: 10.1007/s00431-023-05293-6. <https://pubmed.ncbi.nlm.nih.gov/37875630/>
- Jacob S, Nair AB, Patil A, Boddu SHS. An Updated Overview of the Emerging Role of Patch and Film-Based Buccal Delivery Systems. Pharmaceutics. 2021;13(8):1206. PMID: 34452167. DOI: 10.3390/pharmaceutics13081206. <https://pubmed.ncbi.nlm.nih.gov/34452167/>
- Bartlett JA, van der Voort Maarschalk K. Understanding the Oral Mucosal Absorption and Resulting Clinical Pharmacokinetics of Asenapine. AAPS PharmSciTech. 2012;13(4):1110-1115. PMID: 22936407. DOI: 10.1208/s12249-012-9839-7. <https://pubmed.ncbi.nlm.nih.gov/22936407/>
- Grass J, Rose P, Burhenne J, et al. Absolute Bioavailability of Microdosed Midazolam After Buccal Administration Is Dependent on Buccal Exposure Time. J Clin Pharmacol. 2021;61(4):532-539. PMID: 32976642. DOI: 10.1002/jcph.1751. <https://pubmed.ncbi.nlm.nih.gov/32976642/>
- Jitca G, Muntean DL, Ghibu S, et al. Stability of Oral Liquid Dosage Forms in Pediatric Cardiology: A Prerequisite for Patient's Safety-A Narrative Review. Pharmaceuticals (Basel). 2023;16(5):736. PMID: 37111791. DOI: 10.3390/ph16050736. <https://pubmed.ncbi.nlm.nih.gov/37111791/>
- Ozakar RS, Ozakar E. Current Overview of Oral Thin Films. Turkish Journal of Pharmaceutical Sciences. 2021;18(1):111-121. PMID: 33634686. DOI: 10.4274/tjps.galenos.2020.76390. <https://pubmed.ncbi.nlm.nih.gov/33634686/>
By Jack Zheng, MS Pharmacy — Founder of MIHIYO Labs. Focused on the R&D of high-bioavailability, fast-absorption oral dissolving strips.
0 comments